Regeneron, Sanofi expand antibody alliance with USD 1 billion upfront payment

By Public Technologies
  • Regeneron expanded its immunology alliance with Sanofi to co-develop and co-commercialize four next-generation, long-acting antibodies.
  • Sanofi will pay USD 1 billion upfront; Regeneron can earn up to USD 7 billion in development, regulatory, commercial milestones.
  • Companies will split global development and commercialization costs 50:50; future profits from the new products will also be shared 50:50.
  • Regeneron will lead R&D; Sanofi will lead global commercialization; existing Dupixent profit-sharing terms remain unchanged.
  • REGN20423 is in Phase 1 for atopic dermatitis; three other programs are expected to enter clinical studies in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010100PRIMZONEFULLFEED9837599) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.